Abstract: Dendritic cells (DCs) play an important role in bridging innate and adaptive immunity. These APCs have the ability to recognize specific molecular signatures of pathogens through TLRs. In particular, the intracellular TLR7 and TLR8, mediating the recognition of ssRNA by DCs, play a major role in the immune response during viral infection. Although differences have been identified between TLR7 and TLR8, in terms of cellular expression and functions, the signaling pathways that lead to DC maturation following TLR7 or TLR8 engagement are largely unknown. We compared the signaling pathways involved in human CD34-DC maturation induced by agonists selective for TLR7 (imiquimod) or TLR8 (3M002). TLR7 and TLR8 activation up-regulated CCR7, CD40, CD86, and CD83 expression and IL-6 and IL-12p40 production. However, only TLR8 activation led to IL-12p70 production and il-12p35 mRNA expression. We found that upon TLR7 and TLR8 activation, JNK and NF-B positively regulated the expression of CCR7, CD86, CD83, and CD40 and the production of IL-6 and IL-12p40. However, although p38MAPK participated in the up-regulation of maturation markers in response to TLR7 activation, this kinase exerted an inhibitory effect on CD40 expression and IL-12 production in TLR8-stimulated DCs. We also showed that the Jak/STAT signaling pathway was involved in CD40 expression and cytokine production in TLR7-stimulated DCs but negatively regulated CD83 expression and cytokine secretion in DCs activated through TLR8. This study showed that TLR7 and TLR8 activate similar signaling pathways that play different roles in DC maturation, depending on which TLR is triggered. J. Leukoc. Biol. 85: 000 -000; 2009.
INTRODUCTION
Dendritic cells (DCs), like macrophages and B cells, are potent APCs and play an important role in the initiation and regulation of immune response [1, 2] . DCs form a sentinel network able to detect, capture, and process antigens such as invading bacteria, viruses, tissue damage, and haptens. Upon exposure to "danger" signals, DCs undergo a maturation process characterized by the increased formation of MHC-peptide complexes and the up-regulation of costimulatory molecules (CD86, CD40) and CD83 protein. The maturation process is also characterized by the induction of chemokine receptors that facilitate movement into regional lymph nodes (CCR7) and by the synthesis of cytokines that influence T cell differentiation (IL-6, IL-12, or IL-10) [3] . Many of these danger signals are transduced by TLRs, which are highly conserved receptors that recognize a variety of pathogen-breakdown products including peptidoglycan, lipopeptides (TLR2), dsRNA (TLR3), LPS (TLR4), flagellin (TLR5), ssRNA (TLR7/8), and CpG DNA (TLR9) [4] . Among the TLR family, TLR3, TLR7, TLR8, and TLR9 are not expressed on the cell surface but are retained in endosomal compartments. TLR7 and TLR8 are similar in sequence and together with TLR9, form an evolutionarily related subgroup within the TLR superfamily [5] . TLR7 and TLR8 mediate the recognition of ssRNA by DCs and play a major role in the immune response during viral infection [6, 7] . Recently, synthetic compounds of the imidazoquinoline family have been identified as TLR7 and/or TLR8 agonists [8] . Among these agonists, the lead compound imiquimod, a TLR7 agonist, exerts strong antiviral and antitumoral activities and is being marketed for the treatment of external genital warts caused by human papillomavirus [9] . Moreover, imiquimod-treated DCs are able to induce cancer cell death directly [10] . TLR7 is expressed in plasmacytoid DCs (pDCs) [11, 12] , but its expression in CD11c ϩ myeloid DCs (mDCs) is still controversial [13, 14] . In most studies, TLR7 expression was not detected in human monocyte-derived DCs (Mo-DCs; for review, see ref. [4] ). However, a recent study showed that Mo-DCs and Langerhans cell (LC)-like DCs derived from CD34 ϩ hematopoietic progenitors (CD34-LCs) expressed low levels of TLR7 [15] , suggesting that TLR7 expression may depend on the culture protocol used and the origin of the DCs. In response to TLR7 stimulation, pDCs produce large amounts of IFN-␣ [16] , whereas mDCs produce IL-12 [13] . TLR7 activation also leads to DC maturation and expression of CD40, CD80, CD86 [13] , and CCR7 [11] . TLR8 is expressed in mDCs, monocytes, Mo-DCs, and CD34-LCs [4, 15, 17] . TLR8 activation in mDCs leads to IL-12 and TNF-␣ production [13, 16, 18] and to the up-regulation of CD40, CD80, and CD86 [13, 19] .
Signaling pathways activated following TLR engagement can vary, depending on the recruitment or not of MyD88, which when recruited by most TLRs except for TLR3, forms a complex with members of the IL-1R-associated kinase (IRAK) family (IRAK1 and IRAK4) and TNFR-associated factor 6, which then activates TGF-␤-activated protein kinase 1 (TAK1), which in turn, activates the IB kinase (IKK) complex, leading to IB degradation and NF-B activation. Simultaneously, TAK1 phosphorylates members of the MAPK kinase (MKK) family, such as MKK4, MKK3, or MKK6, which subsequently activate JNK and p38MAPK [20] . All TLR agonists seem to converge on MAPKs and NF-B signaling pathways to exert their biological effects in fine [5] . However, to date, there are no reports showing the involvement of these pathways in the maturation of DCs following TLR7 or TLR8 activation. Some studies have indicated that the activation of the Jak/ STAT signaling pathway can regulate DC maturation [21] [22] [23] [24] or macrophage activation [25] .
In our study, we investigated the involvement of MAPK, NF-B, and Jak/STAT signaling pathways in the maturation of human mDCs derived from CD34 ϩ progenitors (CD34-DCs) induced by the TLR7 or TLR8 agonist. Our results showed that the engagement of TLR7 and TLR8 induced JNK and p38MAPK activation as well as NF-B activity. In addition, we observed the activation of STAT1 and STAT3. Using pharmacological inhibitors, we highlighted a differential involvement of these signaling pathways in DC maturation induced by TLR7 and TLR8 agonists.
MATERIALS AND METHODS

Generation of DCs from human cord blood CD34
ϩ hematopoietic progenitor cells
Umbilical cord blood samples were obtained after full-term delivery from women who were clearly informed about the aim of the study and gave their informed consent. Mononuclear cells were prepared by density centrifugation using medium for lymphocyte isolation (Eurobio, France). Cells bearing the CD34 ϩ antigen were isolated from the mononuclear fraction through magnetic positive selection using MiniMACS separation columns (Miltenyi Biotec, France) and anti-CD34 ϩ antibodies coated on magnetic beads (direct CD34 progenitor cell isolation kits, Miltenyi Biotec). After purification, the isolated cells were 80 -95% CD34 ϩ cells. Cultures were established in the presence of GM-CSF 200 U/ml (Leucomax 400, a kind gift from Novartis, Rueil-Malmaison, France), recombinant human TNF-␣ 50 U/ml (kindly provided by Dr. E. Schmidt, Mainz, Germany), and fetal liver tyrosine kinase 3 ligand (Flt-3L) 50 ng/ml (PeproTech, France) in RPMI 1640 containing Glutamax I supplemented with 10% heat-inactivated FCS, 1 mM sodium pyruvate, 1% penicillin, and streptomycin antibiotic solution (all from Gibco Invitrogen, UK). The cells were then incubated at 3 ϫ ϫ10 5 cells/ml at 37°C in a 5% CO 2 , 95% air atmosphere for 7 days. At Day 7, depending on the donor, Ͻ2.5% of the cells were CD34
ϩ , 40 -50% were CD1a ϩ , 15-20% were CD14 ϩ , 50 -60% were CD86
ϩlow , 90 -95% were CD40 ϩlow , 90 -95% were HLA-DR ϩlow , Ͻ5% were CD83 ϩ , and Ͻ2.5% were CCR7 ϩ .
Chemical treatment of immature DCs
On Day 7, the DCs were washed three times and incubated at 10 6 cells/ml. The cells were then treated with imiquimod (40 M, Sigma Chemical Co., St. Louis, MO, USA) or 3M002 (25 M, 3M Pharmaceuticals, St. Paul, MN, USA) for varying periods of time. In some experiments, the DCs were pretreated for 30 min with SP600125 (20 M, Merck Chemicals Ltd., UK), SB203580 (20 M, Merck Chemicals Ltd.), or Bay 11-7085 (3 M, Merck Chemicals Ltd.). In other experiments, the DCs were treated for 2 h with Jak inhibitor I (Merck Chemicals Ltd.).
Flow cytometry analysis
The cultured DCs were resuspended at 2.5 ϫ 10 5 cells in 30 l culture medium and incubated for 30 min at 4°C with specific mAb or appropriate isotypic controls. After three washes in cold PBS supplemented with 0.5% BSA, the cells were analyzed with a FACSCalibur cell analyzer (Becton Dickinson, France) using CellQuest software (Becton Dickinson). The corrected mean fluorescence intensity (cMFI) was calculated as a ratio between the total MFI obtained using the specific antibody and the total MFI obtained using a control fluorescent antibody of the same isotype. The following mAb were used: PE-conjugated anti-CD86 (B-T7, Diaclone, France), PE-conjugated anti-CCR7 (150503, R&D Systems, France), PE-conjugated anti-CD83 (HB15a, Beckman Coulter, France), and PE-conjugated anti-CD40 (MAB89, Beckman Coulter). Appropriate isotype-irrelevant antibodies were used at the same concentrations as controls.
RT-PCR analysis
The total RNA was extracted after lysis of cells in TRIzol reagent (Invitrogen, France) by the guanidium thiocyanate method as indicated by the manufacturer. The RNA was quantified by spectrophotometry. The first-strand cDNA was synthesized from the total RNA extracted in RNase-free conditions. The reaction was performed on 2 g total RNA with an oligo dT primer (MWG Biotech, Germany) and 2 units avian myeloblastosis virus RT (Promega, France).
The PCR reaction was performed using 1 unit Taq polymerase (MP Biomedical, France). PCR conditions were one cycle of 5 min at 95°C, followed by 25/30 cycles of 30 s at 95°C (␤-actin/ifn-␤ il-12p35), 30 s at 55/57.5/60°C (␤-actin/ifn-␤/il-12p35), 1 min at 72°C, and finishing with 10 min incubation at 72°C. Specific primers used in the PCR reaction mixture were the following (forward and reverse primers, respectively): il-12p35: 5Ј-ACC ACT CCC AAA ACC TGC-3Ј and 5Ј-CCA GGC AAC TCC CAT TAG-3Ј; ifn-␤: 5Ј-AAA CTC ATG AGC AGT CTG CA-3Ј and 5Ј-AGG AGA TCT TCA GTT TCG GAG G-3Ј; ␤-actin: 5Ј-GGG TCA GAA GGA TTC CTA TG-3Ј and 5Ј-GGT CTC AAA CAT GAT CTG GG-3Ј. The PCR products were visualized with the addition of ethidium bromide on 1% agarose gel. ␤-Actin was used to control and calibrate the cDNA synthesis.
Real-time RT-PCR analysis was performed using SYBR Green technology on a LightCycler rapid thermal cycler (Roche Diagnostics, Meylan, France). Forward and reverse primers for tlr7 and tlr8 were described already by Xu et al. [26] . For each set of primers, a Basic Local Alignment Search Tool search revealed that sequence homology was obtained only for the target gene. To confirm the specificity of the amplification, the PCR product was subjected to a melting curve analysis and agarose gel electrophoresis. PCR amplification was performed in duplicate in a total reaction volume of 10 l. The reaction mixture consisted of 1 l diluted template, 2 l FastStart DNA Master PLUS SYBR Green I kit, and 0.5 M forward and reverse primers. After an 8-min activation of Taq polymerase, amplification was allowed to proceed for 30 -45 cycles, each consisting of denaturation at 95°C for 10 s, annealing at 61°C (gapdh), 63°C (tlr8), or 65°C (tlr7) for 5 s, and extension at 72°C for 5 or 9 s, depending on the target gene. Fivefold serial dilutions from soleus total RNA were analyzed for each target gene and allowed us to construct linear standard curves from which the concentrations of the test sample were calculated. Results were normalized to gapdh transcription to compensate for variation in input RNA amounts and efficiency of reverse transcription and were expressed as relative expression.
Western blot analysis
The cultured DCs (10 6 cells/ml) were washed in cold PBS before lysis in 50 l lysis buffer [20 mM Tris (pH 7.4), 137 mM NaCl, 2 mM EDTA (pH 7.4), 1% Triton, 25 mM ␤-glycerophosphate, 1 mM Na 3 VO 4 , 2 mM sodium pyrophosphate, 10% glycerol, 1 mM PMSF, 10 g/ml aprotinin, and 10 g/ml leupeptin]. The homogenates were centrifuged at 15,000 rpm for 20 min at 4°C. Equal amounts of denatured proteins were loaded onto a SDS-PAGE gel and transferred onto a polyvinylidene difluoride membrane (Amersham Biosciences, France). The membranes were then incubated with antibodies raised against the phosphorylated forms of MAPK-activated protein kinase 2 (MAPKAPK-2), p38MAPK, JNK1/2, STAT1, or STAT3 (all from Cell Signaling Technology, Ozyme, France) or IB-␣ (C21, Santa Cruz Biotechnology, France). The membranes were stripped and reprobed with antibodies against total p38MAPK (sc728, Santa Cruz Biotechnology), total JNK, total STAT1, total STAT3 (all from Cell Signaling Technology), or total p65 (sc109, Santa Cruz Biotechnology) as loading controls. Immunoreactive bands were detected by chemiluminescence (ECL solution, Amersham Biosciences).
Oligonucleotide pull-down assay
Following treatments, cells were lysed in Nonidet P-40 (NP-40) lysis hypertonic buffer. In brief, cell pellets were resuspended in buffer containing 0.2% NP-40, 20% glycerol, 20 mM HEPES-KOH, pH 7.9, 420 mM NaCl, 1 mM DTT, 1 mM sodium orthovanadate, 1 mM sodium pyrophosphate, 0.125 M okadaic acid, 62.5 mM EDTA, 40 M EGTA, 0.5 mM PMSF, 1 g/ml leupeptin, 1 g/mL aprotinin, and 1 g/ml pepstatin and incubated with gentle agitation at 4°C for 30 min. Cellular debris was removed by centrifugation at 4°C at 15,000 rpm for 20 min. The following 5Ј-biotin-labeled oligonucleotides (MWG Biotech) were hybridized: 5Ј-TTG AGG GGA CTT TCC CAG G-3Ј and 5Ј-CCT GGG AAA GTC CCC TCA A-3Ј, according to the human NF-B promoter sequence. Mutated oligonucleotides were used as control for unspecific binding (5Ј-TTG AGG CGA CTT TCC CAG G-3Ј and 5Ј-CCT GGG AAA GTC GCC TCA A-3Ј). Whole cell extracts (200 g) were incubated at 4°C for 90 min with 2 g ds 5Ј-biotinylated oligonucleotide coupled to 30 L streptavidin-agarose beads (Sigma Chemical Co.). Complexes were washed in binding buffer and eluted by boiling in reducing sample buffer, and proteins were separated on 8% SDS-PAGE gel followed by Western blot analysis and probed for a p65 level with a p65 antibody (sc-109, Santa Cruz Biotechnology). Whole extract proteins (50 g) were loaded onto 8% SDS-PAGE gel followed by Western blot analysis and probed for the p65 level with a p65 antibody (sc-109, Santa Cruz Biotechnology) for control.
ELISA assays for cytokine production
The culture supernatants of the DCs were removed 24 h after the various treatments and kept at -80°C until cytokine measurement. IL-6, IL-12p40, and IL-12p70 productions were measured using Quantikine immunoassay ELISA kits (R&D Systems) in 96-well microtiter plates according to the manufacturer's instructions. Results were expressed as pg/million cells. The ELISA assay levels of detection were Ͻ0.7 pg/ml for IL-6, Ͻ15 pg/ml for IL-12p40, and Ͻ5 pg/ml for IL-12p70, according to the manufacturer's instructions.
Statistical analysis
The differences between the marker cMFI of the DCs treated with or without inhibitors were evaluated using a Student's t-test. The significance was indicated as *, P Ͻ 0.05, or #, P Ͻ 0.01. All tests were performed using Microsoft Excel software.
RESULTS
TLR7 and TRL8 mRNA expression in CD34-DCs
Results obtained from different laboratories showed that TLR7 expression in in vitro-derived DCs may depend on the differentiation protocol used to obtain the DCs [4] . As shown in Figure 1 , we observed that tlr7 and tlr8 mRNAs were expressed in immature CD34-DCs differentiated in the presence of GM-CSF, TNF-␣, and Flt-3L for 7 days. tlr7 and tlr8 mRNAs were present in monocytes. In Mo-DCs, tlr8 mRNA was largely expressed, conversely to tlr7 mRNA, which was expressed weakly. Moreover, we observed that the TLR8 agonist but not the TLR7 agonist induced Mo-DC maturation (data not shown). Consequently, we chose to use the CD34-DC model to study the effects of TLR7 and TLR8 agonists.
TLR7 and TRL8 agonists induced CD34-DC maturation
In the first part of our study, we evaluated the effects of imiquimod and 3M002, chemical agonists of TLR7 and TLR8, respectively, on a DC phenotype. To compare CD34-DC maturation induced by TLR7 and TLR8 agonists, we tested various concentrations, up to 100 M of the agonists on DC maturation (data not shown). We found that the lowest noncytotoxic concentrations producing the greatest maturation were 40 M and 25 M for imiquimod and 3M002, respectively. These concentrations were then used for subsequent experiments. Both agonists induced DC maturation, characterized by the upregulation of CCR7, CD83, CD40, and CD86 on the cell surface ( Fig. 2A) and the secretion of IL-6 and IL-12p40 (Fig.  2B) . Interestingly, 3M002 induced a greater expression of all markers, especially CD40, and at least a tenfold higher production of IL-6 and IL-12p40 compared with imiquimod. Only 3M002 induced the up-regulation of il-12p35 (Fig. 2C ) and the production of IL-12p70 (Fig. 2D) . We also observed that 3M002 and to a lesser extent, imiquimod caused an increase in ifn-␤ mRNA (Fig. 2C) . We did not observe ifn-␣ mRNA up-regulation by TLR7 or TLR8 agonists (data not shown).
JNK and p38MAPK are involved in CD34-DC maturation induced by TLR7 and TLR8 agonists JNK and p38MAPK are known to be involved in DC maturation induced by TLR4 [27] , TLR9 [28] , TNF-␣ [29] , and contact sensitizers [30, 31] . However, to date, there is no evidence of their involvement in TLR7-or TLR8-induced DC maturation. To determine the potential implication of these MAPKs in TLR7-or TLR8-induced DC maturation, we first evaluated the kinetics of JNK and p38MAPK activation in CD34-DCs stimulated by imiquimod (40 M) or 3M002 (25 M). Imiquimod strongly induced JNK and p38MAPK phosphorylation between 0.5 h and 3 h of treatment (Fig. 3A) . 3M002-induced JNK and p38MAPK activation peaked at 0.5 h and then decreased rapidly (Fig. 3A) . To assess the role of JNK and p38MAPK in CD34-DC maturation induced by imiquimod or 3M002, we used well-known pharmacological inhibitors of these MAPKs. 1 . tlr7 and tlr8 mRNA expressions in CD34-DCs, which were generated by culturing human CD34 ϩ cells from cord blood in the presence of GM-CSF, TNF-␣, and Flt-3L for 7 days. Monocytes (Mono) were obtained from human peripheral blood and differentiated or not into Mo-DCs in the presence of GM-CSF and IL-4 for 5 days. tlr7 and tlr8 expression was measured using real-time RT-PCR. Results were normalized to gapdh. Results are representative of four independent experiments performed on different donors.
As shown in Figure 3B , the JNK inhibitor SP600125 significantly inhibited JNK activation induced by TLR7 or TLR8 agonists, and the p38MAPK inhibitor SB203580 strongly reduced the phosphorylation of MAPKAPK-2, which is activated selectively by p38MAPK. SP600125 only slightly affected p38MAPK activation and IB-␣ expression. Interestingly, SB203580 had no effect on IB-␣ expression but potentiated JNK activation in 3M002-stimulated DCs without affecting the activation of this kinase in untreated or in imiquimod-treated DCs (data not shown). CD34-DCs were pretreated with SP600125 (20 M) or SB203580 (20 M) for 30 min and then stimulated with imiquimod (40 M) or 3M002 (25 M) for 24 h. Cell treatment with inhibitors alone did not affect the DC phenotype (data not shown). Viability of DCs treated with the inhibitors was Ͼ75% (data not shown). JNK inhibition affected the up-regulation of CCR7, CD83, CD86, and CD40 and the secretion of IL-12p40 and IL-6 induced by imiquimod or 3M002 (Fig. 3C) . p38MAPK inhibition also diminished CCR7, CD83, and CD86 expression and IL-6 and IL-12p40 production in imiquimod-treated DC but did not affect CD40 expression (Fig. 3C) . For 3M002-induced DC maturation, the inhibition of p38MAPK diminished the up-regulation of CCR7 and CD83 and the production of IL-6. Interestingly, the inhibition of p38MAPK caused a significant increase of CD40 expression and of IL-12p40 and IL-12p70 production induced by 3M002. These results showed that JNK and p38MAPK were activated but played different roles in TLR7-and TLR8-mediated DC maturation.
TLR7 and TLR8 agonists induced IB-␣ degradation in CD34-DCs
Activation of the NF-B pathway is an important process in DC maturation [32] [33] [34] [35] . NF-B is regulated by the inhibitory molecule IB-␣, which retains NF-B in the cytoplasm under normal conditions. Upon cellular stimulation, IB-␣ is degraded, allowing NF-B to translocate into the nucleus, where it binds to its target promoters [36] . We used the degradation of IB-␣ as a read-out for NF-B activation. DCs were treated with imiquimod (40 M) or 3M002 (25 M) for varying periods of time. Both agonists induced IB-␣ degradation between 0.5 h and 1 h of treatment (Fig. 4A) . Using the NF-B inhibitor Bay 11-7085, we assessed the involvement of the NF-B pathway in the maturation of CD34-DCs induced by imiquimod or 3M002. We observed in our model that Bay 11-7085 was a potent inhibitor of the DNA-binding activity of the p65 NF-B subunit and also strongly diminished p65 expression (Fig. 4B) . However, we observed that Bay 11-7085 induced JNK and p38MAPK phosphorylation (data not shown). Treatment of the DCs with Bay 11-7085 alone did not affect their phenotype, and the viability of DC treated with Bay 11-7085 was more than 75% (data not shown). Treatment with Bay 11-7085 inhibited the up-regulation of CCR7, CD83, CD86, and CD40 significantly. The production of IL-12p40 and IL-6 induced by the TLR7 or the TLR8 agonist was abrogated totally by Bay 11-7085 (Fig. 4C) . Bay 11-7085 also inhibited IL-12p70 production induced by 3M002 (Fig. 4C) . NF-B activation seems to be crucial in TLR7-and TLR8-mediated DC maturation, as observed with other TLRs.
The Jak/STAT signaling pathway is involved in CD34-DC maturation induced by TLR7 and TLR8 agonists Recent studies have shown that the Jak/STAT signaling pathway was activated following TLR4 activation [25, [37] [38] [39] . Moreover, STAT1 seems to play a role in DC maturation induced by LPS [21, 22] . This prompted us to study the activation of different members of the STAT family in DCs stimulated with TLR7 or TLR8 agonists. As shown in Figure 5A , imiquimod induced the phosphorylation of STAT1 and STAT3 on serine and tyrosine residues at 0.5 h and 2 h of treatment, respectively. The TLR8 agonist 3M002 also activated STAT1 and STAT3 with tyrosine phosphorylation detected at 1 h and 2 h of treatment (Fig. 5A) . We neither observed STAT5 nor STAT6 activation following imiquimod or 3M002 treatment (data not shown). We then used an inhibitor of Jak kinases (Jak inhibitor I) to assess the implication of this signaling pathway in DC maturation induced by imiquimod or 3M002. As shown in Figure 5B , Jak inhibitor I was a potent inhibitor of STAT1 and STAT3 activation induced by TLR7 and TLR8 agonists. Moreover, this inhibitor neither affected JNK and p38MAPK activation nor IB-␣ expression (data not shown). Treatment with the inhibitor alone neither affected the DC phenotype nor the DC viability (data not shown). Inhibition of the Jak/STAT signaling pathway in imiquimod-stimulated DCs reduced CD40 expression and the production of IL-6 and IL-12p40 (Fig. 5C ) but had no effect on the other markers. In 3M002-treated DCs, the Jak inhibitor also reduced CD40 expression, but we observed a significant enhancement of CD83 expression and IL-12p40 and IL-12p70 production. As for MAPKs, our results highlight the differential involvement of the Jak/STAT pathway in TLR7-and TLR8-mediated DC maturation.
STAT1/3 activation induced by TLR7 or TLR8 agonists depends on NF-B signaling pathway activation
We tested the effect of the NF-B inhibitor on STAT1 and STAT3 activation in imiquimod or 3M002-stimulated DCs. As shown in Figure 6 , pretreatment with Bay 11-7085 abolished tyrosine-phosphorylation of STAT1 and STAT3. This indicated that activation of the NF-B signaling pathway was required for the activation of STAT1 and STAT3 by TLR7 or TLR8 agonists in DCs, suggesting an indirect mechanism of action for STAT phosphorylation. STAT1 tyrosine phosphorylation following TLR engagement has been described mostly as an indirect mechanism involving the production of IFNs [40] , and IL-6 is known to induce STAT3 activation in DCs [41] . In addition, TLR stimulation can provoke IL-6 release rapidly [42, 43] , and we observed that IL-6 mRNA was induced by TLR7 and TLR8 agonists after 1 h of treatment (data not shown). As the NF-B signaling pathway inhibition totally impaired the production of IL-6 induced by imiquimod and 3M002, we suggest that STAT1 and STAT3 tyrosine phosphorylation could be a result of the release of cytokines such as IFN-␤ and IL-6, respectively.
DISCUSSION
TLR7 and TLR8 belong to a subfamily of TLRs that mediates the recognition of pathogen-associated molecular patterns in an endosomal compartment [7] . As a result of the lack of TLR8-selective agonists, most studies before 2005 did not differentiate between the functions of TLR7 and TLR8. In 2005, using selective, synthetic ligands for TLR7 and TLR8, Gorden and colleagues [18] revealed functional differences between human TLR7 and TLR8, in terms of cell selectivity and a cytokine induction profile. However, to date, the signaling pathways activated selectively by TLR7 and TLR8 and the involvement of these pathways in DC maturation have not been described. In this study, we investigated the role of MAPK, NF-B, and Jak/STAT signaling pathways in DC maturation induced by TLR7 or TLR8. Human CD34-DCs were used, as expression of tlr7 and tlr8 mRNAs was present in these cells, and CD34-DCs responded to TLR7 and TLR8 agonists. On the contrary, MoDCs only expressed tlr8 mRNA and were not suitable for our study. Previous studies have reported that human monocytes expressed TLR8 [4, 14] . Concerning TLR7 expression, results are more conflicting, as its expression seems to depend on the donor [4, 14] . In our study, we observed that freshly isolated monocytes from four independent donors expressed tlr7 and tlr8 mRNAs. To compare DC maturation induced by TLR7 or TLR8 stimulation, we used the well-known TLR7-selective agonist imiquimod [8] or the TLR8-selective agonist 3M002 [18] at the lowest, noncytotoxic concentrations that induced the greatest DC maturation.
Imiquimod-and 3M002-induced CD34-DC maturation was characterized by the up-regulation of CD83, CD86, CD40, and CCR7 and by the secretion of IL-6 and IL-12p40. Interestingly, DCs stimulated with 3M002 expressed higher levels of all markers and cytokines than imiquimod-activated DCs. R848, an agonist of TLR7 and TLR8, up-regulates CD86, CD80, CD40, and CD83 expression and the secretion of IL-12 and IL-6 in different models of mDCs [13, 44] . Imiquimod was found to up-regulate CD40, CD86, and CD80 on pDCs and mDCs [13] . We also observed that the TLR8 agonist but not the TLR7 agonist induced IL-12p70 production. As the p35 subunit of IL-12 is the limiting factor for IL-12p70 production, this difference in IL-12p70 production between imiquimod and 3M002 could be explained by the observation that il-12p35 mRNA was up-regulated only by 3M002 but not by imiquimod. This result is in agreement with studies showing that R848-treated Mo-DCs produced IL-12p70 [40, [45] [46] [47] . Other studies performed with human blood-derived mDCs and PBMCs also showed IL-12p70 production in response to 3M002 stimulation [18, 48] . Although we observed a great enhancement of ifn-␤ mRNA in 3M002-treated DCs and to a lesser extent, in imiquimod-treated DCs, we could not detect this cytokine in DC supernatants. However, it has been reported that type I IFN can activate their receptors even when the cytokine is not detected in cell supernatants [40] . Moreover, endogenous type I IFN production has been shown to participate in IL-12p70 production by regulating il-12p35 mRNA expression [40] . During the last decade, TLR7/8 ligands have been used as cancer vaccine adjuvants, notably because of their ability to induce APC activation. As TLR8-selective agonists are available only since 2005, most of these studies were conducted with imiquimod [49] . Besides, Xu et al. [44] have shown that TLR8-primed DCs produced IL-12p70, leading to the induction of CD8 ϩ T cells that displayed high functional avidity with enhanced tumor cell recognition. The observation that the 3M002 was more effective to induce DC activation than imiquimod, notably by inducing IL-12p70 production, suggests that the use of the TLR8 ligand may be beneficial as a vaccine adjuvant.
MAPK [28, 29, 50] and NF-B signaling pathways are central for DC maturation [5] . As expected, imiquimod and 3M002 induced JNK and p38MAPK activation. JNK activation induced by imiquimod was sustained, and 3M002 induced a transient phosphorylation of JNK. In macrophages, imiquimod has been shown to induce TLR7-mediated p38MAPK phosphorylation [51] , and the TLR7/8 agonist R848 provoked JNK and p38MAPK activation [52] . R848 also induced p38MAPK phosphorylation in eosinophils [53] and monocytes [19, 54] . Until now, there has been no evidence of an involvement of MAPK in TLR7-and TLR8-mediated DC maturation. Using pharmacological inhibitors, we found that JNK and p38MAPK participated in the up-regulation of CCR7, CD83, CD40, and CD86, as well as in the production of IL-6 and IL-12p40 by the TLR7 agonist. Bohnenkamp and colleagues [45] described the involvement of p38MAPK in R848-mediated production of IL-12p70 in Mo-DCs. JNK has also been shown to play a role in IL-6 production induced by R848 in murine B cells [55] , but in eosinophils, imiquimod-induced production of IL-6 involves p38MAPK but not JNK [56] . For the TLR8 agonist, JNK was involved in DC maturation as it was for imiquimod. However, with regard to p38MAPK, only the up-regulation of CCR7 and CD83 and the production of IL-6 were dependent on this kinase. Interestingly, the inhibition of p38MAPK activity augmented the expression of CD40 and the production of IL-12p40 and IL-12p70 induced by the TLR8 agonist 3M002, suggesting an inhibitory effect of p38MAPK on these parameters. These observations were unexpected, as most of the studies conducted in DCs activated with different stimuli (such as LPS, TNF-␣, CD40 ligand or contact sensitizers) indicated that p38MAPK had no effect on CD40 up-regulation and regulated CD86 expression and IL-12 production positively [50] . However, the fact that the p38MAPK inhibitor specifically potentiated 3M002-mediated activation of JNK revealed a possible link between these two MAPKs occurring only in the TLR8 signaling cascade. This inhibitory effect of p38MAPK on JNK activation could explain the up-regulation of CD40 expression and of IL-12p40/p70 production provoked by the SB203580. However, other markers that are also dependent on JNK ac- tivity, such as CCR7, CD83. or IL-6, are not up-regulated by the p38MAPK inhibitor, suggesting other mechanisms.
In our model of human CD34-DCs, imiquimod and 3M002 activated the NF-B pathway, confirming what was already shown in the mouse cell line XS52 [57] , in human monocytes [19] , in macrophages [52] , and in TLR8-transfected 293 cells [58] . Using a pharmacological inhibitor of IKK activity, we showed that the NF-B pathway was strongly involved in DC maturation induced by TLR7 and TLR8 agonists. This is in agreement with the fact that IKK-␣-deficient mice are not able to produce IL-12p40 under R848 stimulation [59] . However, we observed that the Bay 11-7085 also induced JNK and p38MAPK activation in untreated cells and potentiated the activation of these kinases in TLR7-and TLR8-stimulated DCs. Thus, we could not exclude that the inhibitory effects that we observed resulted in nonspecific actions of the inhibitor. Nevertheless, the strong inhibition of DC maturation that we observed in the presence of Bay 11-7085 in TLR7-and TLR8-activated DCs suggests that the concomitant activation of JNK and p38MAPK by the inhibitor had minor effects compared with the inhibition of NF-B p65 activity and expression.
Activation of the Jak/STAT signaling pathway has been identified recently as one of the elements participating in DC maturation upon TLR stimulation. Indeed, STAT1 participates in IL-12 production by DCs [21, 24, 40] . However, STAT3 has been described as having an inhibitory effect on DC activation [23, 41] . We observed in CD34-DCs that imiquimod and 3M002 induced STAT1 and STAT3 activation. Gautier and colleagues [40] have shown that STAT1 was phosphorylated in Mo-DCs or in mouse DCs in response to R848. In addition, TLR7 agonists induce STAT1 activation in macrophages [24] and STAT3 activation in chronic lymphocytic leukemia cells [60] . Using an inhibitor of Jaks, we found that activation of the Jak/STAT signaling pathway participated in the up-regulation of CD40 and in the production of IL-6 and IL-12p40 by CD34-DCs stimulated by the TLR7 agonist imiquimod. Recently, it has been shown that LPS-induced CD40 expression [21, 22] and R848-induced IL-12 production in murine DCs required STAT1 activation [40] . However, we did not find the same results when stimulating DCs with the TLR8 agonist 3M002. In this case, inhibition of Jak activity down-regulated CD40 expression, had no role in IL-6 production, and surprisingly, augmented CD83 expression and IL-12p40 and IL12p70 production. The differential involvement of the Jak/ STAT signaling pathway in TLR7-or TLR8-induced IL-12p40 production could be a result of the induction of a negative regulatory loop mechanism, such as suppressor of cytokine signaling 1 (SOCS1). However, we did not observe any differences in socs1 mRNA expression between TLR7-and TLR8-stimulated DCs (data not shown).
The inhibition of NF-B totally impaired TLR7-or TLR8-mediated activation of STAT1 and STAT3, suggesting that STAT1 and STAT3 were activated indirectly following TLR7 or TLR8 engagement. As IL-6 production and ifn-␤ mRNA (data not shown) up-regulation induced by imiquimod and 3M002 were also totally inhibited by Bay 11-7085, we suggest that STAT1 and STAT3 activation could be a result of the production of IFN-␤ and IL-6, respectively.
In summary, this work shows that JNK and NF-B are involved similarly and strongly in DC maturation induced by TLR7 and TLR8 agonists. On the other hand, p38MAPK and the Jak/STAT signaling pathway have different roles in TLR7-or TLR8-mediated DC maturation. These two pathways, upon TLR8 triggering, negatively control IL-12 and selectively CD40 (p38MAPK) and CD83 (Jak/STAT). TLR7 and TLR8 are often seen as closely related TLRs because of their phylogenetic relationship and their common cellular localization. However, our study highlights the fact that TLR7 and TLR8 engagement brings into play different signaling pathways in the DC maturation process (Fig. 7) . Fig. 7 . Involvement of different signaling pathways in CD34-DC maturation induced by TLR7 or TLR8 agonists. (A) In human CD34-DCs, the TLR7 agonist imiquimod activates JNK, p38MAPK, and NF-B, which positively regulate the expression of CCR7, CD86, and CD83 and the production of IL-6 and IL-12p40. CD40 up-regulation is under the control of JNK and NF-B but not of p38MAPK. Imiquimod activates STAT1 and STAT3 indirectly, probably by the production of IFN-␤ and IL-6, respectively. STAT1/3 activation participates in the positive regulation of CD40 expression and IL-6 and IL-12p40 production. (B) The TLR8 agonist 3M002 activates JNK, p38MAPK, and NF-B, which positively regulate the expression of CD83 and CCR7 and the production of IL-6. JNK and NF-B are also involved in the up-regulation of CD40 and CD86 and in the production of IL-12p40/p70. Conversely, p38MAPK restrains CD40 expression and IL-12p40/p70 production. 3M002 activates STAT1 and STAT3 indirectly, probably by the production of IFN-␤ and IL-6, respectively. STAT1/3 activation participates in the positive regulation of CD40 expression but exerts an inhibitory effect on CD83 expression and IL-12p40/p70 production.
